Olodaterol

Drug Profile

Olodaterol

Alternative Names: BI-1744; BI-1744-CL; BI1774CL; Olodaterol hydrochloride; Striverdi Respimat

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Amines; Benzoxazines; Bronchodilators; Ketones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • No development reported Asthma

Most Recent Events

  • 28 Oct 2014 Efficacy and adverse events data from the ANHELTO 1 and 2 phase III trials in Chronic obstructive pulmonary disease presented at the 80th Annual Meeting of the American College of Chest Physicians (ACCP-2014)
  • 09 Oct 2014 Launched for Chronic obstructive pulmonary disease in USA (Inhalation)
  • 01 Aug 2014 Registered for Chronic obstructive pulmonary disease in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top